Alborz Bulk Pharmaceutical Raw Materials Company (DBALK) income statement
Operating revenue through to net profit and earnings per share
- Ticker
- DBALK
- Industry
- Pharmaceuticals
- Market
- Iran Fara Bourse
Latest periods
| Item | To 1405/06/31 | To 1404/06/31 | To 1403/06/31 | To 1402/06/31 | To 1401/06/31 | To 1400/06/31 |
|---|---|---|---|---|---|---|
| Operating revenue | 15,574,712 | 7,641,991 | 5,044,933 | 4,665,220 | 1,898,277 | 1,726,481 |
| Cost of operating revenue | -10,897,880 | -5,390,260 | -3,720,103 | -3,158,735 | -1,153,652 | -1,127,410 |
| Gross profit (loss) | 4,676,832 | 2,251,731 | 1,324,830 | 1,506,485 | 744,625 | 599,071 |
| Selling, general and administrative expenses | -645,790 | -438,780 | -267,200 | -175,503 | -123,583 | -78,921 |
| Other income | 100,987 | 17,935 | 13,754 | 82,269 | 1,478 | 0 |
| Other expenses | -246,117 | -167,475 | -65,027 | -109,141 | -23,717 | -11,614 |
| Operating profit (loss) | 3,885,912 | 1,663,411 | 1,006,357 | 1,304,110 | 598,803 | 508,536 |
| Finance costs | -932,450 | -644,980 | -801,725 | -487,141 | -189,557 | -139,869 |
| Other non-operating income and expenses | -23,350 | 8,970 | 139,202 | 63,536 | 4,840 | 19,234 |
| Profit (loss) from continuing operations before tax | 2,930,112 | 1,027,401 | 343,834 | 880,505 | 414,086 | 387,901 |
| Current year tax | -579,720 | -157,910 | -45,121 | -198,114 | -72,465 | -87,278 |
| Net profit (loss) from continuing operations | 2,350,392 | 869,491 | 298,713 | 682,391 | 341,621 | 288,034 |
| Net profit (loss) | 2,350,392 | 869,491 | 298,713 | 682,391 | 341,621 | 288,034 |
| Basic earnings (loss) per share | 1,311 rials | 0 rials | 0 rials | 974 rials | 615 rials | 785 rials |
| Net earnings (loss) per share, rials | 1,292 rials | 478 rials | 325 rials | 887 rials | 657 rials | 779 rials |
| Capital | 1,820,000 | 1,820,000 | 920,000 | 770,000 | 520,000 | 370,000 |
Reporting periods
63 periods are on file for this report, from the period ending 1390/12/29 to the period ending 1405/06/31.